Generic placeholder image

Recent Patents on Anti-Infective Drug Discovery


ISSN (Print): 1574-891X
ISSN (Online): 2212-4071

Current Update on Eosinophilic Lung Diseases and Anti-IL-5 Treatment

Author(s): Konstantinos Samitas, Madeleine Radinger and Apostolos Bossios

Volume 6, Issue 3, 2011

Page: [189 - 205] Pages: 17

DOI: 10.2174/157489111796887855

Price: $65


Peripheral blood eosinophilia and eosinophilic lung inflammation are common in a variety of pulmonary conditions, including eosinophilic pneumonia and asthma, hypereosinophilic syndrome and Churg-Strauss syndrome. Therapy in most of these clinical entities consists of long-term treatment with systemic corticosteroids, which is not always successful and has substantial side-effects. Interest has increased considerably regarding alternative corticosteroid-sparing “smart” regimens in these diseases that target IL-5, an important regulator of eosinophilic development and function. To date, two humanized monoclonal antibodies, mepolizumab and reslizumab, have been developed that bind to human IL-5. In addition a new monoclonal antibody (MEDI-563) has been recently developed targeting the IL-5 receptor. This review will investigate the current status on IL-5 targeted therapy and related patents regarding eosinophil-driven respiratory diseases, primarily eosinophilic asthma but also CSS and HES. Recent advances and information from clinical trials will be presented in a way that will allow the reader to approach the role of the eosinophil in the lung diseases presented in this review.

Keywords: Churg-Strauss syndrome, Eosinophilia, eosinophilic asthma, hypereosinophilic syndrome, interleukin-5, MEDI-563, mepolizumab, reslizumab, ANTI-IL5 TREATMENT, Vascular endothelial growth factor

Next »

Rights & Permissions Print Export Cite as
© 2024 Bentham Science Publishers | Privacy Policy